Aligos Therapeutics (NASDAQ:ALGS) Upgraded to “Strong-Buy” at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Aligos Therapeutics (NASDAQ:ALGS) to a strong-buy rating in a research report released on Thursday morning,Zacks.com reports.

ALGS has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Finally, Westpark Capital began coverage on Aligos Therapeutics in a research note on Thursday, March 26th. They issued a “buy” rating and a $48.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $37.20.

Aligos Therapeutics Stock Up 2.0%

Shares of NASDAQ:ALGS opened at $5.71 on Thursday. Aligos Therapeutics has a 12-month low of $5.12 and a 12-month high of $13.69. The stock has a market cap of $35.34 million, a PE ratio of -0.66 and a beta of 2.28. The business has a 50 day moving average of $6.91 and a 200-day moving average of $7.92.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The company had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $0.25 million. Equities research analysts expect that Aligos Therapeutics will post -7.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Woodline Partners LP acquired a new stake in Aligos Therapeutics in the first quarter valued at $2,602,000. Marshall Wace LLP acquired a new stake in Aligos Therapeutics in the fourth quarter valued at $2,504,000. Bank of America Corp DE increased its holdings in Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares during the period. Readystate Asset Management LP increased its holdings in Aligos Therapeutics by 48.5% in the third quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock valued at $1,991,000 after purchasing an additional 66,331 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Aligos Therapeutics by 22.8% in the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after purchasing an additional 31,913 shares during the period. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.